C-Reactive Protein in Human Atherogenesis: Facts and Fiction
The role of C-reactive protein (CRP) in atherosclerosis is controversially discussed. Whereas initial experimental studies suggested a pathogenic role for CRP in atherogenesis, more recent genetic data from Mendelian randomization trials failed to provide evidence for a causative role of CRP in card...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/561428 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568260529225728 |
|---|---|
| author | Oliver Zimmermann Kefei Li Myron Zaczkiewicz Matthias Graf Zhongmin Liu Jan Torzewski |
| author_facet | Oliver Zimmermann Kefei Li Myron Zaczkiewicz Matthias Graf Zhongmin Liu Jan Torzewski |
| author_sort | Oliver Zimmermann |
| collection | DOAJ |
| description | The role of C-reactive protein (CRP) in atherosclerosis is controversially discussed. Whereas initial experimental studies suggested a pathogenic role for CRP in atherogenesis, more recent genetic data from Mendelian randomization trials failed to provide evidence for a causative role of CRP in cardiovascular disease. Also, experimental results from laboratories all over the world were indeed contradictory, partly because of species differences in CRP biology and partly because data were not accurately evaluated. Here we summarize the published data from experimental work with mainly human material in order to avoid confusion based on species differences in CRP biology. Experimental work needs to be reevaluated after reconsideration of some traditional rules in research: (1) in order to understand a molecule’s role in disease it may be helpful to be aware of its role in physiology; (2) it is necessary to define the disease entity that experimental CRP research deals with; (3) the scientific consensus is as follows: do not try to prove your hypothesis. Specific CRP inhibition followed by use of CRP inhibitors in controlled clinical trials may be the only way to prove or disprove a causative role for CRP in cardiovascular disease. |
| format | Article |
| id | doaj-art-ff64fb3367f64f3784a42a1b0b55e076 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-ff64fb3367f64f3784a42a1b0b55e0762025-02-03T00:59:33ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/561428561428C-Reactive Protein in Human Atherogenesis: Facts and FictionOliver Zimmermann0Kefei Li1Myron Zaczkiewicz2Matthias Graf3Zhongmin Liu4Jan Torzewski5Cardiovascular Center Oberallgäu-Kempten, Robert Weixler Street 50, 87439 Kempten, GermanySino-German Heart Centre, Shanghai East Hospital, Shanghai, ChinaCardiovascular Center Oberallgäu-Kempten, Robert Weixler Street 50, 87439 Kempten, GermanyCardiovascular Center Oberallgäu-Kempten, Robert Weixler Street 50, 87439 Kempten, GermanySino-German Heart Centre, Shanghai East Hospital, Shanghai, ChinaCardiovascular Center Oberallgäu-Kempten, Robert Weixler Street 50, 87439 Kempten, GermanyThe role of C-reactive protein (CRP) in atherosclerosis is controversially discussed. Whereas initial experimental studies suggested a pathogenic role for CRP in atherogenesis, more recent genetic data from Mendelian randomization trials failed to provide evidence for a causative role of CRP in cardiovascular disease. Also, experimental results from laboratories all over the world were indeed contradictory, partly because of species differences in CRP biology and partly because data were not accurately evaluated. Here we summarize the published data from experimental work with mainly human material in order to avoid confusion based on species differences in CRP biology. Experimental work needs to be reevaluated after reconsideration of some traditional rules in research: (1) in order to understand a molecule’s role in disease it may be helpful to be aware of its role in physiology; (2) it is necessary to define the disease entity that experimental CRP research deals with; (3) the scientific consensus is as follows: do not try to prove your hypothesis. Specific CRP inhibition followed by use of CRP inhibitors in controlled clinical trials may be the only way to prove or disprove a causative role for CRP in cardiovascular disease.http://dx.doi.org/10.1155/2014/561428 |
| spellingShingle | Oliver Zimmermann Kefei Li Myron Zaczkiewicz Matthias Graf Zhongmin Liu Jan Torzewski C-Reactive Protein in Human Atherogenesis: Facts and Fiction Mediators of Inflammation |
| title | C-Reactive Protein in Human Atherogenesis: Facts and Fiction |
| title_full | C-Reactive Protein in Human Atherogenesis: Facts and Fiction |
| title_fullStr | C-Reactive Protein in Human Atherogenesis: Facts and Fiction |
| title_full_unstemmed | C-Reactive Protein in Human Atherogenesis: Facts and Fiction |
| title_short | C-Reactive Protein in Human Atherogenesis: Facts and Fiction |
| title_sort | c reactive protein in human atherogenesis facts and fiction |
| url | http://dx.doi.org/10.1155/2014/561428 |
| work_keys_str_mv | AT oliverzimmermann creactiveproteininhumanatherogenesisfactsandfiction AT kefeili creactiveproteininhumanatherogenesisfactsandfiction AT myronzaczkiewicz creactiveproteininhumanatherogenesisfactsandfiction AT matthiasgraf creactiveproteininhumanatherogenesisfactsandfiction AT zhongminliu creactiveproteininhumanatherogenesisfactsandfiction AT jantorzewski creactiveproteininhumanatherogenesisfactsandfiction |